Involuntary Weight Loss

Author(s):  
Bruce Leff
2018 ◽  
Author(s):  
L John Hoffer

This review explains starvation as both a physiologic process and a disease. It includes a detailed explanation of the modifying effects of metabolic adaptation and systemic inflammation, as interpreted in a clinical context. It navigates the reader through the difficult shoals of vague and conflicting terminology that burden this topic and provides current definitions and nuanced explanations of the important but frequently misunderstood terms related to starvation and its modifiers and consequences. It provides a succinct explanation of the physiology of total fasting and its clinical correlates. Finally, it explains the interactions among starvation, sarcopenia, frailty, involuntary weight loss, systemic inflammation, cachexia, and disuse muscle atrophy. The multiple and interacting causes of generalized muscle atrophy are pointed out. Inadequate appreciation of these interactions can result in failure to diagnose and treat starvation-induced diseases. A clinical approach to involuntary weight loss is outlined.   This review contains 6 figures, 2 tables and 56 references Key words: adaptation, cachexia, frailty, hypoalbuminemia, inflammation, ketosis, kwashiorkor, malnutrition, marasmus, muscle atrophy, protein-energy malnutrition, sarcopenia, starvation, systemic inflammation, weight loss


2019 ◽  
Vol 493 ◽  
pp. S127-S128
Author(s):  
C. Figols ◽  
J. Trapé ◽  
J. Aligué ◽  
A. Arnau ◽  
A. San José ◽  
...  

2016 ◽  
Vol 64 (4) ◽  
pp. 899-900 ◽  
Author(s):  
Onán Pérez-Hernández ◽  
José María González-Pérez ◽  
Antonio Martínez-Riera ◽  
María del Carmen Durán-Castellón ◽  
María Blanca Monereo-Muñoz ◽  
...  

Endocrinology ◽  
2013 ◽  
Vol 154 (9) ◽  
pp. 3118-3129 ◽  
Author(s):  
Jose M. Garcia ◽  
Thomas Scherer ◽  
Ji-an Chen ◽  
Bobby Guillory ◽  
Anriada Nassif ◽  
...  

Cachexia, defined as an involuntary weight loss ≥5%, is a serious and dose-limiting side effect of chemotherapy that decreases survival in cancer patients. Alterations in lipid metabolism are thought to cause the lipodystrophy commonly associated with cachexia. Ghrelin has been proposed to ameliorate the alterations in lipid metabolism due to its orexigenic and anabolic properties. However, the mechanisms of action through which ghrelin could potentially ameliorate chemotherapy-associated cachexia have not been elucidated. The objectives of this study were to identify mechanisms by which the chemotherapeutic agent cisplatin alters lipid metabolism and to establish the role of ghrelin in reversing cachexia. Cisplatin-induced weight and fat loss were prevented by ghrelin. Cisplatin increased markers of lipolysis in white adipose tissue (WAT) and of β-oxidation in liver and WAT and suppressed lipogenesis in liver, WAT, and muscle. Ghrelin prevented the imbalance between lipolysis, β-oxidation, and lipogenesis in WAT and muscle. Pair-feeding experiments demonstrated that the effects of cisplatin and ghrelin on lipogenesis, but not on lipolysis and β-oxidation, were due to a reduction in food intake. Thus, ghrelin prevents cisplatin-induced weight and fat loss by restoring adipose tissue functionality. An increase in caloric intake further enhances the anabolic effects of ghrelin.


Sign in / Sign up

Export Citation Format

Share Document